Hangcheng Fu, MD

Hangcheng Fu, MD
Urology department, Shanghai Cancer Center of Fudan Univeristy,
Mainly interested in molecular type and immunotype of Renal cell carcinoma and Bladder cell carcinoma,
Publication:
First author and co-first author SCI Publications:
1. High NUCB2 expression level represents an independent negative prognostic factor in Chinese cohorts of non-metastatic clear cell renal cell carcinoma patients. Fu H, Zhu Y, Wang Y, Liu Z, Zhang J, Wang Z, Xie H, Dai B, Xu J, Ye D. Oncotarget. 2016 Oct 28 (IF:5.008)
2. Low Expression of Mucin-4 Predicts Poor Prognosis in Patients With Clear-Cell Renal Cell Carcinoma. Fu H, Liu Y, Xu L, Chang Y, Zhou L, Zhang W, Yang Y, Xu J. Medicine (Baltimore). 2016 Apr. (IF:2.133)
3. Galectin-9 predicts postoperative recurrence and survival of patients with clear-cell renal cell carcinoma. Fu H, Liu Y, Xu L, Liu W, Fu Q, Liu H, Zhang W, Xu J. Tumour Biol. 2015 Aug;36(8) (IF:3.611)
4. A three-molecule score based on Notch pathway predicts poor prognosis in non-metastasis clear cell renal cell carcinoma. Liu Z, Fu Q, Fu H, Wang Z, Xu L, An H, Li Y, Xu J. Oncotarget. 2016 Sep 6. (IF:5.008)

Disclosure information not submitted.

Presentation(s):

• PD25-05: Chronic exposure of physiological concentration of Arsenic induced bladder malignancy in preclinical models

  Sunday, April 30, 2023
  7:40 AM – 7:50 AM CST